View More Recent Stories
-
AstraZeneca (AZN) announces CAPItello-290 Phase III trial did not meet endpoints
-
AstraZeneca (AZN) announces IMFINZI plus chemotherapy approved in the US
-
AstraZeneca (AZN): TAGRISSO granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
-
AstraZeneca (AZN) announces Tagrisso granted FDA Priority Review for patients with unresectable, Stage III EGFR-mutated lung cancer

